Logo
Friday, 26 April 2024
Tuesday, 10 Dec 2019 07:00 pm

FDA Warns 15 Companies for Illegally Marketing Cannabidiol Containing Products

The U.S. Food and Drug Administration has issued a new regulation on cannabidiol (CBD) that warned its chances of causing liver injury and many other damages to the human body. FDA has specifically given warning to 15 companies for unlawfully selling several merchandises having CBD as ingredient. Also, the FDA specified that it cannot define CBD being recognized as safe (GRAS) amongst skilled experts for using it in human or animal food.

newsImage
 

CBD is being advertised in various types of product, such as capsules, oil drops, syrups, food products like chocolate bars & teas as well as topical lotions & creams. A few have publicized it having several homeopathic properties like anxiety, relieving pain and even boosting hair growth. As per the outlines of FDA warning letters, these companies are making use of online stores, product webpages as well as social media for marketing CBD products in interstate commerce using methods that are against the FD&C Act, such as marketing CBD products for treating diseases or else for several other therapeutic procedures for humans and animals. Furthermore, other violations consist of marketing CBD products as dietary supplements as well as adding CBD to human and animal foods.

The FDA had sent warning letters lately to several companies selling CBD products illegally in interstate trade that appealed of preventing, diagnosing, mitigating, treating or even curing severe diseases, like cancer, or otherwise violated the FD&C Act. A few of the products were in added violation as CBD were added to foodstuff and some were even marketed as dietary supplements regardless of them not meeting the standards of dietary supplements.

Under the FD&C Act, any produce anticipated to treat a disease or else having a therapeutic usage, as well as any produce (excluding food) intended to affect the functioning of human or animal body is called a drug. The FDA hasn’t given approval to any product of CBD except of one prescription human drug used for treating severe and rare forms of epilepsy. There is very restricted data in terms of the other marketed products having CBD that might probably vary in terms of composition from that of the FDA-permitted product. Also, there are chances of such products not been evaluated for possible adverse effects over the human body.

The FDA has demanded responses from the all he 15 companies in 15 working days mentioning the correction measures they plan to follow for violating the regulation. Any company failing to correct the defilements promptly might effect in legal action, along with product seizure and injunction. 

 


Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.


Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
© The News and Media Division of The Insight Partners 2024 | All Rights Reserved | Privacy Policy